Daiwa: Insilico Medicine (03696.HK) BD and PCC output hit record highs; first-half revenue rose 287.2% year-on-year to US$106 million

Zhitong Finance APP has learned that Daiwa has issued a research report stating that Insilico Medicine (03696.HK) achieved record-high BD and PCC output, and its sharp revenue increase in the first half of this year was mainly driven by accelerated outbound licensing activities. First-half revenue rose 287.2% year on year to US$106 million, with substantial growth in its core drug discovery and pipeline development business.